Mehran Abolbashari1. 1. Division of Cardiovascular Medicine, Texas Tech University Health Sciences Center El Paso, 4800 Alberta Avenue, El Paso, TX, 79905, USA. mehran.abolbashari@ttuhsc.edu.
Abstract
PURPOSE OF REVIEW: This review aims to evaluate the major cardiovascular adverse events (MACE) and antithrombotic approaches in concomitant atrial fibrillation (AF) and atherosclerosis. RECENT FINDINGS: MACE in concomitant AF and atherosclerosis has been evaluated in recent studies. A recent retrospective study of 2670 patients with AF revealed that atherosclerosis burden with AF can be a marker of adverse vascular outcomes with extracranial atherosclerosis as a potent predictor of MACE. Trials to evaluate the antithrombotic approaches in concomitant atherosclerotic disease and AF has been mainly in patients with coronary artery disease (CAD). AFIRE trial demonstrated that in patients with AF and stable CAD rivaroxaban alone is not inferior to rivaroxaban plus aspirin with better safety profile. Atherosclerosis is common in AF and poses additional risk to patients. Antithrombotic management of atherosclerosis in AF is not well investigated and needs further trial to identify the subgroups that benefit from more intensive antithrombotic measures.
PURPOSE OF REVIEW: This review aims to evaluate the major cardiovascular adverse events (MACE) and antithrombotic approaches in concomitant atrial fibrillation (AF) and atherosclerosis. RECENT FINDINGS: MACE in concomitant AF and atherosclerosis has been evaluated in recent studies. A recent retrospective study of 2670 patients with AF revealed that atherosclerosis burden with AF can be a marker of adverse vascular outcomes with extracranial atherosclerosis as a potent predictor of MACE. Trials to evaluate the antithrombotic approaches in concomitant atherosclerotic disease and AF has been mainly in patients with coronary artery disease (CAD). AFIRE trial demonstrated that in patients with AF and stable CAD rivaroxaban alone is not inferior to rivaroxaban plus aspirin with better safety profile. Atherosclerosis is common in AF and poses additional risk to patients. Antithrombotic management of atherosclerosis in AF is not well investigated and needs further trial to identify the subgroups that benefit from more intensive antithrombotic measures.
Authors: Joshua D Bundy; Susan R Heckbert; Lin Y Chen; Donald M Lloyd-Jones; Philip Greenland Journal: Am J Cardiol Date: 2019-10-10 Impact factor: 2.778
Authors: Kristian Wachtell; Björn Hornestam; Mika Lehto; David J Slotwiner; Eva Gerdts; Michael H Olsen; Peter Aurup; Björn Dahlöf; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Lars H Lindholm; Markku S Nieminen; Jens Rokkedal; Richard B Devereux Journal: J Am Coll Cardiol Date: 2005-03-01 Impact factor: 24.094
Authors: Jan Heeringa; Deirdre A M van der Kuip; Albert Hofman; Jan A Kors; Gerard van Herpen; Bruno H Ch Stricker; Theo Stijnen; Gregory Y H Lip; Jacqueline C M Witteman Journal: Eur Heart J Date: 2006-03-09 Impact factor: 29.983
Authors: Christina Magnussen; Teemu J Niiranen; Francisco M Ojeda; Francesco Gianfagna; Stefan Blankenberg; Inger Njølstad; Erkki Vartiainen; Susana Sans; Gerard Pasterkamp; Maria Hughes; Simona Costanzo; Maria Benedetta Donati; Pekka Jousilahti; Allan Linneberg; Tarja Palosaari; Giovanni de Gaetano; Martin Bobak; Hester M den Ruijter; Ellisiv Mathiesen; Torben Jørgensen; Stefan Söderberg; Kari Kuulasmaa; Tanja Zeller; Licia Iacoviello; Veikko Salomaa; Renate B Schnabel Journal: Circulation Date: 2017-10-16 Impact factor: 29.690
Authors: Gerhard Hindricks; Tatjana Potpara; Nikolaos Dagres; Elena Arbelo; Jeroen J Bax; Carina Blomström-Lundqvist; Giuseppe Boriani; Manuel Castella; Gheorghe-Andrei Dan; Polychronis E Dilaveris; Laurent Fauchier; Gerasimos Filippatos; Jonathan M Kalman; Mark La Meir; Deirdre A Lane; Jean-Pierre Lebeau; Maddalena Lettino; Gregory Y H Lip; Fausto J Pinto; G Neil Thomas; Marco Valgimigli; Isabelle C Van Gelder; Bart P Van Putte; Caroline L Watkins Journal: Eur Heart J Date: 2021-02-01 Impact factor: 29.983
Authors: Tommy Andersson; Anders Magnuson; Ing-Liss Bryngelsson; Ole Frøbert; Karin M Henriksson; Nils Edvardsson; Dritan Poçi Journal: Eur Heart J Date: 2013-01-14 Impact factor: 29.983